- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02128854
Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills (TABLETS)
May 5, 2017 updated by: Medical University of South Carolina
The purpose of this project is two-fold: (1) to determine the feasibility of recruiting rural African American (AA) adults in South Carolina (SC) for assessing the usefulness of tablet-based resources in good diabetes self-management behaviors, and (2) to test a tablet-aided intervention for improving diabetes self-management behaviors
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The proposed study will assess the feasibility of recruitment of African American adults residing in rural South Carolina who will assist with improving the usability of tablet computers.
In addition, we will implement a pilot trial of the TABLETS (Tablet-Aided BehavioraL intervention Effect on Self-management skills) intervention for diabetes, using motivational strategies, among rural African Americans.
The proposed project is designed to address 3 important issues: recruitment for a hard-to-reach population, utility of technology-enabled intervention, and development of a tablet-aided intervention tailored to understand best practices for diabetes self-management
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥45 years
- Clinical diagnosis of diabetes with HbA1c ≥8% and either diagnosis of hyperlipidemia with LDL >100mg/dL or hypertension with BP >140/80mmHg
- Self-identified as African American
- Residence in a 4G cellular service area
- Able to communicate in English
Exclusion Criteria:
- Cognitive impairment
- Active alcohol or drug abuse/dependency
- Acute decompensation of chronic conditions precluding participation
- Participation in other diabetes clinical trials
- A life expectancy <6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tablets Intervention
Individuals randomized to this arm will receive: 1) peripheral devices for monitoring blood glucose, blood pressure, and weight; 2) 8 weekly tablet-delivered education and skills training sessions; 3) two booster sessions delivered via tablet-based videoconferencing at 3 and 6 months.
|
The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes.
Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors.
Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
|
No Intervention: Usual Care
Apart from study visits, individuals randomized to the Usual Care group will receive usual care for diabetes management as provided by their primary care physician.
The provider will be responsible for determining changes in the treatment regimen and determining the timing of follow-up visits for diabetes care.
Between scheduled office encounters, contact will be initiated by the individual.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-Monitoring Behavior Using the Summary of Diabetes Self-Care Activities
Time Frame: 6 months post-randomization
|
This will be done to assess self-management behaviors for diabetes.
|
6 months post-randomization
|
Physical Activity Score on the Global Physical Activity Questionnaire
Time Frame: 6 months post-randomization
|
Information will be collected to assess physical activity in three domains and sedentary behaviors.
|
6 months post-randomization
|
Medication Adherence on the Morisky Medication Adherence Scale
Time Frame: 6 months post-randomization
|
Scale will be used to assess specific medication-taking behaviors.
|
6 months post-randomization
|
Diet Score on the Rapid Eating and Activity Assessment for Participants
Time Frame: 6 months post-randomization
|
Dietary intake will be assessed.
|
6 months post-randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycosylated Hemoglobin A1c (HbA1c)
Time Frame: 6 months post-randomization
|
Blood specimens (10cc of blood) will be obtained at baseline, 2, and 6-month visits for HbA1c.
|
6 months post-randomization
|
Low-Density Lipoprotein Cholesterol (LDL-c)
Time Frame: 6 months post-randomization
|
Blood specimens (10cc of blood) will be obtained at baseline, 2, and 6-month visits for non-fasting lipids.
|
6 months post-randomization
|
Blood Pressure
Time Frame: 6 months post-randomization
|
Blood pressure (BP) readings will be obtained using automated BP monitors.
The device will be programmed to take 3 readings at 2 minute intervals, and give an average of the 3 BP readings.
|
6 months post-randomization
|
Cardiovascular Disease (CVD) Risk Using the Framingham Risk Score
Time Frame: 6 months post-randomization
|
This score will be used to estimate the 10-year risk for coronary heart disease outcomes (i.e., heart attack, death) according to 7 factors (age, gender, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, high blood pressure medication use, and smoking status).
|
6 months post-randomization
|
Quality of Life Using the Medical Outcomes Study Short Form
Time Frame: 6 months post-randomization
|
We will obtain summary physical and mental health quality of life scores.
|
6 months post-randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Cheryl P Lynch, MD, MPH, Medical University of South Carolina
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 14, 2014
Primary Completion (Actual)
July 26, 2016
Study Completion (Actual)
August 31, 2016
Study Registration Dates
First Submitted
April 18, 2014
First Submitted That Met QC Criteria
April 29, 2014
First Posted (Estimate)
May 1, 2014
Study Record Updates
Last Update Posted (Actual)
May 9, 2017
Last Update Submitted That Met QC Criteria
May 5, 2017
Last Verified
September 1, 2016
More Information
Terms related to this study
Keywords
- Diabetes Mellitus, Type 2
- African Americans
- Randomized Control Trial
- Diabetes Mellitus, Type II
- Controlled Clinical Trial
- Behavioral Research
- Behavioral Medicine
- Diabetes Mellitus, Non-Insulin-Dependent
- Blacks
- Diabetes Mellitus, Adult-Onset
- Diabetes Mellitus, Noninsulin Dependent
- Non-Hispanic Blacks
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00021502
- R03DK098489-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
There are no plans to share IPD during the analysis phase.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Tablets Intervention
-
American Regent, Inc.CompletedIron Deficiency Anemia Secondary to IBD or Gastric Bypass
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Trevi TherapeuticsCompletedPrurigo NodularisUnited States, Austria, France, Germany, Poland
-
Cara Therapeutics, Inc.RecruitingPruritus | Notalgia ParestheticaUnited States, Poland, Spain, Canada, Germany
-
VaxartCompletedRespiratory Syncytial Virus (RSV)United States
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedInflammatory Bowel DiseasesChina
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingModerate to Severe Atopic DermatitisChina
-
Shenzhen NewDEL Biotech, Co., LtdShenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.Enrolling by invitation
-
Akros Pharma Inc.CompletedSkin Diseases | Psoriasis | Plaque PsoriasisUnited States, Canada, Poland
-
Jiangsu HengRui Medicine Co., Ltd.Completed